- 1
- 2 Hypertension in pregnancy

3 The significance of mitochondrial haplogroups in preeclampsia risk

- 4 Kristina Wendelboe Olsen (0000-0002-3902-200X)¹, Paula L. Hedley (0000-0001-5801-960X)^{2,3},
- 5 Christian M. Hagen (0000-0002-0513-7722)^{2,4}, Line Rode (0000-0002-9080-3389)⁵, Sophie Placing²,
- 6 Karen R Wøjdemann(0000-0002-6707-1677)⁷, Anne-Cathrine Shalmi⁶, Karin Sundberg(0000-0001-
- 7 5598-5773)⁸, Anne Nørremølle (0000-0003-2561-7683)⁹, Ann Tabor (0000-0001-7450-1543)^{8,10},
- 8 Joanna L. Elson (0000-0002-3551-5624)^{2,11*} & Michael Christiansen (0000-0003-4713-755X)^{2,4}

9 ¹*Fertility Department, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark*

10 ²Department for Congenital Disorders, Statens Serum Institut, 2300 Copenhagen, Denmark

- 11 ³ Brazen Bio, Los Angeles, California, USA
- 12 ⁴ Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
- 13 ⁵ Department of Clinical Biochemistry, Copenhagen University Hospital Rigshospitalet, 2600 Glostrup
- ⁶ Department of Obstetrics, Hillerød Sygehus, 3400 Hillerød, Denmark
- 15 ⁷Department of Gynecology and Obstetrics, Bornholm Hospital, 3700 Rønne, Bornholm, Denmark
- ⁸ Center of Fetal Medicine, Department of Obstetrics, Copenhagen University Hospital Rigshospitalet, 2100
 Copenhagen, Denmark
- 18 ⁹ Department of Cellular and Molecular Medicine, University of Copenhagen, Denmark
- ¹⁰ Department of Clinical Medicine, Faculty of Medical and Health Sciences, University of Copenhagen, 2200
 Copenhagen, Denmark
- 21 ¹¹ Biosciences Institute Newcastle University, Newcastle UK
- 22 Short title: mtDNA haplogroups in Preeclampsia
- 23 Journal: Hypertension in Pregnancy
- 24 Word Count: 2539 words
- 25 *corresponding author
- 26 Joanna L. Elson, Ph.D

- 27 Institute of Genetic Medicine
- 28 International Centre for Life,
- 29 Central Parkway, Newcastle upon Tyne, NE1 3BZ, United Kingdom
- 30 E.mail: j.l.elson@ncl.ac.uk

31 **Graphical Abstract** (to be submitted separately)



Retrospective study using samples from the Copenhagen First Trimester Study





78 preeclamptic

mtDNA haplotyped using RT-PCR or Sanger sequencing





The difference between mtDNA haplogroups and the risk of preeclampsia was non-significant



33 The significance of mitochondrial haplogroups in preeclampsia risk

34	Objective: To determine whether mitochondrial haplogroups function as disease-modifiers or as
35	susceptibility factors in preeclampsia using a traditional haplogroup association model.
36	Methods: This retrospective study haplotyped 235 control and 78 preeclamptic pregnancies from
37	Denmark using either real-time PCR or Sanger sequencing depending on the rarity of the
38	haplogroup.
39	Results: No significant association between haplogroups and the risk of preeclampsia was found,
40	nor was any role for haplogroups in disease severity uncovered.
41	Conclusion: Mitochondrial haplogroups are not associated with preeclampsia or the severity of
42	preeclampsia in the Danish population. However, this study cannot exclude a role for less
43	common mtDNA variation. Models that can examine these should be applied in preeclamptic
44	patients.

45 Key Words: pregnancy; preeclampsia; mitochondrial DNA; mitochondrial haplogroups

46 Introduction

Preeclampsia affects 2-7 % of all pregnancies in the western world, and is the greatest cause of 47 48 maternal mortality and morbidity worldwide [1-3]. It is a multisystem pregnancy disorder diagnosed by 49 the presence of hypertension and proteinuria with symptoms varying from mild hypertension, 50 proteinuria and edema to multi-organ failure [2, 4, 5]. Preeclampsia has a poorly understood etiology, but it is believed to be influenced by genetic, immunological and environmental factors [6]. Two 51 52 clinical syndromes results from preeclampsia; one in the mother and one in the fetus [4]. The maternal syndrome is characterized by hypertension, frequently proteinuria, or other systemic abnormalities. In 53 54 the United Kingdom the main cause of maternal mortality among preeclampsia cases is pulmonary 55 edema [7]. PE is associated with metabolic, cardiac and other disorders later in life for both mother and child [5]. 56

57 By definition preeclampsia develops after the 20th week and can be classified as early-onset or late-onset; before or after the 34th week of gestation [8]; it can occur with or without intrauterine 58 59 growth restriction [9] and has been associated with respiratory distress in very low birth weight 60 infants [10]. The risk for adverse neonatal outcome is increased with early-onset preeclampsia [6], which, together with restricted fetal growth is associated with high incidence of stillbirth and perinatal 61 death [11]. Preeclampsia can be divided into two-stage disease: Stage I, the asymptomatic stage with 62 63 abnormal placentation, and stage II, during which clinical signs and symptoms develop [12, 13]. Preeclampsia is the result of changes initiated in the first trimester of pregnancy [14]. Preventative 64 65 treatment, with low dose aspirin, started late in the first trimester, has been recommended for high-risk pregnancies [15]. However, the risk of developing preeclampsia is typically – and increasingly -66 67 assessed using either demographic variables or clinical history and or biomarkers [16-18].

68 In healthy pregnancies the placentation begins with the blastocysts adhering to the uterine 69 endometrium (decidua) and forming invasive extravillous cytotrophoblast cells. These cells invade the 70 uterine wall by changing their phenotype from epithelia to endothelia to create vessels for the placental 71 circulation. The predominant theory of the pathogenesis of preeclampsia is that the cytotrophoblasts 72 fail to switch their phenotype, which leads to small, poorly developed spiral arteries resulting in a 73 compromised maternal-fetal blood flow [19]. Persistent defective placental perfusion produces 74 placental hypoxia which will subsequently lead to oxidative stress [20, 21]. Oxidative stress has been 75 shown to be present in placental tissue, moreover there is a higher level of oxidative stress in 76 preeclampsia and other pregnancy-related pathologies [22, 23], indeed, higher levels of oxidative stress 77 have been shown to be present prior to the diagnosis of PE [24]. Furthermore, aberrant placental energy 78 metabolism may explain some of the signs and symptoms of preeclampsia [25], and mitochondrial 79 proteins have also been associated with apoptosis, oxidative stress, reactive oxygen species (ROS) 80 generation and mitochondrial damage [26]. This suggests that mitochondria play a role in the 81 development of preeclampsia.

82 The mitochondria are responsible for producing the majority of cellular ATP by oxidative 83 phosphorylation which also produces ROS such as superoxide (O2-) and hydrogen peroxide (H2O2). It 84 has been assumed that these ROS are continually generated as a result of mitochondrial respiration and 85 are key to some disease processes as well as ageing [27]. Our understanding of ROS has increased in 86 recent years following the elucidation of their role as signaling molecules [28]. The presence of 87 mitochondrial DNA (mtDNA), the mitochondria's own genetic material, is unique among cellular 88 organelles. This circular, double stranded molecule encompasses ~16 kbp of DNA in humans [29]. It 89 codes for 13 polypeptides of the mitochondrial respiratory chain, two ribosomal RNAs and the 22 90 transfer RNAs necessary for the mitochondrial protein synthesis in the matrix. All other mitochondrial

proteins are encoded by nuclear genes. Each mammalian cell contains several hundreds or thousands of
mitochondria depending on the cell's energy demands [30]. MtDNA is maternally inherited which
means the evolution of mtDNA is defined by the emergence of distinct lineages called
haplogroups [31]. Variation in mtDNA has been linked to a number of complex traits [32, 33] and it
has been suggested that this might be linked to differential mitochondrial performance but this is a
controversial field [34].
Torbergsen and coworkers were the first to discover a high incidence of preeclampsia in

98 families with mitochondrial dysfunction [35]; an indication that mitochondria are involved in 99 preeclampsia [36, 37] and thus potentially mtDNA variation could affect the function of the placenta, 100 and thereby lead to the development of preeclampsia. The mitochondrial haplogroup H, by far the most 101 frequent in Denmark [38], has been shown by some to have higher VO2max but is also associated with 102 increased mitochondrial oxidative stress compared to some other haplogroups [39, 40]. These studies 103 have been supported by more recent work looking at athletic performance [41], and an association to 104 heart disease [42]. As with many observations in the mitochondrial association field this has been 105 controversial [43]. However, we hypothesized that, if this were true, haplogroup H will be 106 overrepresented in first-trimester pregnancies which would go on to develop preeclampsia compared to 107 non-complicated pregnancies. The idea of comparing haplogroup H to other European groups has been 108 taken due to the high frequency of haplogroup H in the European population [44].

109 Materials and Methods

110 *Study populations*

111	The study cohort comprised of 78 Danish women with preeclampsia and a control group of 235
112	pregnant Danish women. The study was a case-control sub study, using patients where dried blood spot
113	samples were available, of the Copenhagen First Trimester Screening Study (CFTSS) [45]. Several
114	biomarker studies in PE have been conducted as sub studies of the CFTSS [46-49]. The clinical and
115	demographical data of participants are given in table 1. General population control data were obtained
116	from the Copenhagen City Heart Study (Østerbroundersøgelsen) [50], where the haplotyping is based
117	on haplogroup specific markers in the hypervariable regions (HV1 and HV2) of the mtDNA.
118	In this study, preeclampsia was defined according to the guidelines of the Danish Society for
119	Obstetrics and Gynecology (www.dsog.dk)[51], except that proteinuria was required. The maternal
120	systolic blood pressure should be more than 140 mmHg and diastolic blood pressure more than 90 mm
120 121	systolic blood pressure should be more than 140 mmHg and diastolic blood pressure more than 90 mm Hg, along with ≥ 0.3 g protein in a urine specimen after 20 weeks of gestation in women with
120 121 122	systolic blood pressure should be more than 140 mmHg and diastolic blood pressure more than 90 mm Hg, along with ≥ 0.3 g protein in a urine specimen after 20 weeks of gestation in women with previously normal blood pressure. Severe PE had BP > 160 mm Hg (sys) and/or 110 mm Hg(dia)
120 121 122 123	<pre>systolic blood pressure should be more than 140 mmHg and diastolic blood pressure more than 90 mm Hg, along with ≥ 0.3 g protein in a urine specimen after 20 weeks of gestation in women with previously normal blood pressure. Severe PE had BP > 160 mm Hg (sys) and/or 110 mm Hg(dia) and/or severe organ involvement, as defined in the guidelines[51]. HELLP syndrome required</pre>

125 Haplotyping of mtDNA

126 For the determination of mitochondrial haplogroup all 78 patients and 235 controls were haplotyped.

- 127 Most of them were haplotyped using TaqMan real time PCR [52], while individuals with an
- 128 uncommon haplogroup were examined with Sanger Sequencing.

129 *Statistics*

- 130 Frequencies of all mitochondrial haplogroups in preeclamptic patients and controls were tested for
- 131 independence using Fisher's exact test as appropriate. Similarly, frequencies of mitochondrial
- haplogroups were compared between controls from a general population study and pregnancy controls.
- 133 Odds-ratios and 95% confidence intervals were calculated.

134 *Ethics statement*

- 135 The Copenhagen First Trimester Screening Study was conducted according to the guidelines of the
- 136 Declaration of Helsinki and approved by the Scientific ethics committee of the cities of Copenhagen
- and Frederiksberg (No. (KF) 01-288/97) and the Data protection Agency[45].

138 Results

139 Haplogroup distribution

- 140 The distribution of haplogroups in preeclamptic pregnancies as well as control pregnancies and in a
- 141 Danish population control group [45, 50] is given in table 2. These results were obtained from the
- 142 TaqMan real time PCR and the Sanger Sequencing.

143 Validation of pregnancy controls

144 To investigate whether or not the pregnancy controls from CFTSS are representative for the Danish

145 population, Fishers exact test was performed to compare them with the haplogroup distribution in a

146 general Danish population [45], table 3. It shows that there were no significant differences, therefore, it

147 can be concluded that the pregnancy control group is representative for the general Danish population.

148 Haplogroup distribution and preeclampsia and severity of preeclampsia

149 The data did not support a link between European haplogroups and PE, table 4. None of the

150 uncorrected p-values indicate significance when comparing the control pregnancies with the PE

151 pregnancies, with the value for the most common of the European haplogroups H being p=0.55. Note

- 152 that there was no difference when the PE pregnancies were compared to the general Danish population.
- The PE cases were divided into mild (PE 1), severe (PE 2), and HELLP cases (PE 3), Table 1.
 The distribution of clinical severity as a function of mtDNA haplogroups is depicted in Figure 1. No
 difference was seen; however, the statistical power is very limited.

156 **Discussion**

157 Several health and disease states have been found to be associated with the different mitochondrial

haplogroups [<u>33</u>, <u>42</u>]. In this study the association between the mitochondrial haplogroups and the

159 development of preeclampsia was studied in an attempt to determine if mitochondrial haplogroups

160 function as disease-modifiers or as susceptibility factors in preeclampsia using a traditional haplogroup

161 association model.

The placenta plays an important role in development of preeclampsia [<u>19</u>, <u>36</u>]. As mitochondria are maternally inherited [<u>53</u>], the fetus, the placenta and the mother have the same mitochondrial haplogroup; consequently, the placental mtDNA haplogroup can be determined from a blood sample from either the mother or – in retrospective studies – from the child.

Blood and clinical data from 78 patients with preeclampsia and 235 healthy pregnancy controls were employed to investigate the possibility that preeclampsia is associated with haplogroup H as such an association has been demonstrated in Danish hypertrophic cardiomyopathy patients [42]. Since haplogroup H exhibits increased ROS production, oxidative damage and higher VO2max [39, 40] the preeclamptic women are hypothesized to be more likely to have haplogroup H compared to the controls due to the association between preeclampsia and oxidative stress [21, 24].

The CFTSS pregnancy controls were validated by comparing them with the haplogroup distribution from a Danish general population study. This comparison showed no significant differences (p-value between 0.13-0.79 in a Fisher's exact test), thus the controls fit the distribution seen in the general population, table 2. The haplogroup distribution of preeclamptic patients and healthy controls was compared with Fisher's exact test. No significant difference in the haplogroup distribution between the different groups (P = 0.98) was found, table 3. When haplogroup H was

178 compared with non-H haplogroups there was likewise no significant difference (P = 0.60). The same is 179 true for the other haplogroups with p-values > 0.05, table 3.

180 It has also been suggested that mtDNA haplogroups might affect the course of disease [54]. The 181 severity of preeclampsia might be associated with different haplogroups. With more cases of severe 182 preeclampsia, it is possible that mitochondrial haplogroups could be proven to predict the 183 severity/phenotype of the disease. The same might be true for early-onset versus late-onset 184 preeclampsia, since many researchers suggest that they follow two separate pathogenic pathways [55, 185 56], they might also be associated with different mitochondrial haplogroups. However, our data on 186 severity does not support that this should be the case. And the use of a small number of patients makes 187 the time of birth largely determined by clinical assessment and not biology. It can be difficult to collect 188 data from severe preeclamptic patients, since almost all women in Denmark make use of the offer of 189 free medical care and therefore are often treated before the disease develops to more severe stages. 190 Thus, there might be an undetected association.

Haplogroup H was not found to be associated with preeclampsia, but that does not exclude an association with some of the other haplogroups instead. Because haplogroup J, U, T and K function as disease-modifiers in other diseases they could be the new association candidates. However, to get enough statistical power a larger cohort will be needed or another population with a different haplogroup distribution; a population with high proportion of J, U, T or K. In larger association studies involving rarer mtDNA variants or rare haplogroups it will, however, be very important to account for nuclear genomic differences [57].

The placental mtDNA content (mtDNA copy number) has shown to be a molecular marker of mitochondrial damage and mitochondrial inflammation [58]. Exposure to particulate matter in third trimester has been shown to be associated with mitochondrial damage exemplified by a lower mtDNA

- 201 content [58]. A significant decrease in mtDNA content is also observed in placenta from smokers
- 202 compared with non-smokers [59]. Since environmental factors show this impact on mitochondria, it
- 203 might be that the same can be seen in preeclampsia, only with lower mtDNA content already in the first
- trimester where the placenta is poorly implanted. The dysfunctional placental mitochondria in
- 205 preeclampsia might be due to a small copy number of mtDNA in the first trimester of pregnancy [60,
- 206 <u>61</u>].

207 Conclusion

- 208 A significant association between mtDNA haplogroups and the risk of preeclampsia was not
- 209 demonstrated. However, the diversity of the haplogroups found makes it possible that haplogroups with
- 210 low prevalence may actually play a role for occurrence or clinical presentation of PE. There is currently
- 211 no basis for considering mtDNA haplogroups potential first trimester risk markers of PE.

212 Acknowledgements

- 213 We would like to acknowledge the technical assistance of Dennis Jelsbak Schmidt. This research has
- been conducted using the Danish National Biobank resource, supported by the Novo Nordisk
- 215 Foundation.

217 **References**

 Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph KS. Maternal morbidity associated with earlyonset and late-onset preeclampsia. Obstetrics and gynecology. 2014;124(4):771-81. Epub 2014/09/10. doi: 10.1097/AOG.00000000000472. PubMed PMID: 25198279.

Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130-7. Epub
 2009/05/26. doi: 10.1053/j.semperi.2009.02.010. PubMed PMID: 19464502.

3. Moodley J, Soma-Pillay P, Buchmann E, Pattinson RC. Hypertensive disorders in pregnancy: 2019
 National guideline. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

225 2019;109(9):12723. Epub 2019/10/23. PubMed PMID: 31635598.

 226
 4.
 Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet (London, England).

 227
 2010;376(9741):631-44. Epub 2010/07/06. doi: 10.1016/S0140-6736(10)60279-6. PubMed PMID: 20598363.

 229
 Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet (London, England).

228 5. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. Lancet (London, England).

2021;398(10297):341-54. Epub 2021/05/31. doi: 10.1016/S0140-6736(20)32335-7. PubMed PMID: 34051884.
6. Agarwal A, Aponte-Mellado A, Premkumar BJ, Shaman A, Gupta S. The effects of oxidative stress on
female reproduction: a review. Reproductive biology and endocrinology : RB&E. 2012;10:49. Epub 2012/07/04.

doi: 10.1186/1477-7827-10-49. PubMed PMID: 22748101; PubMed Central PMCID: PMCPMC3527168.

233 7. Walker JJ. Pre-eclampsia. Lancet (London, England). 2000;356(9237):1260-5. Epub 2000/11/10. doi:
 234 10.1016/S0140-6736(00)02800-2. PubMed PMID: 11072961.

Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, et al. Screening for preeclampsia using
 first-trimester serum markers and uterine artery Doppler in nulliparous women. American journal of obstetrics
 and gynecology. 2010;203(4):383 e1-8. Epub 2010/08/10. doi: 10.1016/j.ajog.2010.06.014. PubMed PMID:
 20691410.

9. Milosevic-Stevanovic J, Krstic M, Radovic-Janosevic D, Stefanovic M, Antic V, Djordjevic I. Preeclampsia
with and without intrauterine growth restriction-Two pathogenetically different entities? Hypertens
Pregnancy. 2016;35(4):573-82. Epub 2016/11/03. doi: 10.1080/10641955.2016.1212872. PubMed PMID:
27624400.

Wen YH, Yang HI, Chou HC, Chen CY, Hsieh WS, Tsou KI, et al. Association of Maternal Preeclampsia
with Neonatal Respiratory Distress Syndrome in Very-Low-Birth-Weight Infants. Sci Rep. 2019;9(1):13212. Epub
2019/09/15. doi: 10.1038/s41598-019-49561-8. PubMed PMID: 31519996; PubMed Central PMCID:
PMCPMC6744454.

Weiler J, Tong S, Palmer KR. Is fetal growth restriction associated with a more severe maternal
phenotype in the setting of early onset pre-eclampsia? A retrospective study. PloS one. 2011;6(10):e26937.
Epub 2011/11/03. doi: 10.1371/journal.pone.0026937. PubMed PMID: 22046419; PubMed Central PMCID:
PMCPMC3203930.

251 12. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta.
262 2009;30 Suppl A:S32-7. Epub 2008/12/17. doi: 10.1016/j.placenta.2008.11.009. PubMed PMID: 19070896;
253 PubMed Central PMCID: PMCPMC2680383.

Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and Future
Cardiovascular Health: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2).
Epub 2017/02/24. doi: 10.1161/CIRCOUTCOMES.116.003497. PubMed PMID: 28228456.

257 14. Burton GJ, Cindrova-Davies T, Yung HW, Jauniaux E. HYPOXIA AND REPRODUCTIVE HEALTH: Oxygen
258 and development of the human placenta. Reproduction. 2021;161(1):F53-F65. Epub 2020/05/22. doi:
259 10.1530/REP-20-0153. PubMed PMID: 32438347.

260 15. Committee on Obstetric P, Medicine. SfM-F. ACOG Committee Opinion No. 743: Low-Dose Aspirin Use
 261 During Pregnancy. Obstetrics and gynecology. 2018;132(1):e44-e52. Epub 2018/06/26. doi:

262 10.1097/AOG.000000000002708. PubMed PMID: 29939940.

Tan MY, Syngelaki A, Poon LC, Rolnik DL, O'Gorman N, Delgado JL, et al. Screening for pre-eclampsia by
maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 2018;52(2):186-95.
Epub 20180711. doi: 10.1002/uog.19112. PubMed PMID: 29896812.

266 17. Wright D, Tan MY, O'Gorman N, Poon LC, Syngelaki A, Wright A, et al. Predictive performance of the
 267 competing risk model in screening for preeclampsia. American journal of obstetrics and gynecology.

268 2019;220(2):199 e1- e13. Epub 20181114. doi: 10.1016/j.ajog.2018.11.1087. PubMed PMID: 30447210.

18. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of
 controlled studies. BMJ. 2005;330(7491):565. Epub 2005/03/04. doi: 10.1136/bmj.38380.674340.E0. PubMed
 PMID: 15743856; PubMed Central PMCID: PMCPMC554027.

272 19. Siddiqui N, Hladunewich M. Understanding the link between the placenta and future cardiovascular
273 disease. Trends in cardiovascular medicine. 2011;21(7):188-93. Epub 2012/08/08. doi:

274 10.1016/j.tcm.2012.05.008. PubMed PMID: 22867697.

275 20. Valenzuela FJ, Perez-Sepulveda A, Torres MJ, Correa P, Repetto GM, Illanes SE. Pathogenesis of
276 preeclampsia: the genetic component. Journal of pregnancy. 2012;2012:632732. Epub 2011/12/17. doi:
277 10.1155 (2012) (2022722) P. LAM, J. P.

277 10.1155/2012/632732. PubMed PMID: 22175024; PubMed Central PMCID: PMCPMC3235819.

27821.Abad C, Proverbio T, Pinero S, Botana D, Chiarello DI, Marin R, et al. Preeclampsia, placenta, oxidative279stress, and PMCA. Hypertens Pregnancy. 2012;31(4):427-41. Epub 2012/06/09. doi:

280 10.3109/10641955.2012.690058. PubMed PMID: 22676487.

281 22. Mannaerts D, Faes E, Cos P, Briede JJ, Gyselaers W, Cornette J, et al. Oxidative stress in healthy
282 pregnancy and preeclampsia is linked to chronic inflammation, iron status and vascular function. PloS one.
283 2018;13(9):e0202919. Epub 2018/09/12. doi: 10.1371/journal.pone.0202919. PubMed PMID: 30204759;
284 PubMed Central PMCID: PMCPMC6133366.

23. Gupta S, Aziz N, Sekhon L, Agarwal R, Mansour G, Li J, et al. Lipid peroxidation and antioxidant status in
preeclampsia: a systematic review. Obstetrical & gynecological survey. 2009;64(11):750-9. Epub 2009/10/24.
doi: 10.1097/OGX.0b013e3181bea0ac. PubMed PMID: 19849867.

24. Ahmad IM, Zimmerman MC, Moore TA. Oxidative stress in early pregnancy and the risk of
preeclampsia. Pregnancy hypertension. 2019;18:99-102. Epub 2019/10/07. doi: 10.1016/j.preghy.2019.09.014.
PubMed PMID: 31586785; PubMed Central PMCID: PMCPMC6941664.

25. Aye I, Aiken CE, Charnock-Jones DS, Smith GCS. Placental energy metabolism in health and diseasesignificance of development and implications for preeclampsia. American journal of obstetrics and gynecology.
2022;226(2S):S928-S44. Epub 20201113. doi: 10.1016/j.ajog.2020.11.005. PubMed PMID: 33189710.

294 26. Shi Z, Long W, Zhao C, Guo X, Shen R, Ding H. Comparative proteomics analysis suggests that placental 295 mitochondria are involved in the development of pre-eclampsia. PloS one. 2013;8(5):e64351. Epub

 296
 2013/05/15. doi: 10.1371/journal.pone.0064351. PubMed PMID: 23671712; PubMed Central PMCID:

 297
 PMCPMC3650054.

298 27. Harman D. The biologic clock: the mitochondria? Journal of the American Geriatrics Society.

299 1972;20(4):145-7. Epub 1972/04/01. doi: 10.1111/j.1532-5415.1972.tb00787.x. PubMed PMID: 5016631.

300 28. Stefanatos R, Sanz A. The role of mitochondrial ROS in the aging brain. FEBS letters. 2018;592(5):743 301 58. Epub 2017/11/07. doi: 10.1002/1873-3468.12902. PubMed PMID: 29106705.

Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N. Reanalysis and revision
of the Cambridge reference sequence for human mitochondrial DNA. Nature genetics. 1999;23(2):147. Epub
1999/10/03. doi: 10.1038/13779. PubMed PMID: 10508508.

30. Tuppen HA, Blakely EL, Turnbull DM, Taylor RW. Mitochondrial DNA mutations and human disease.
306 Biochimica et biophysica acta. 2010;1797(2):113-28. Epub 2009/09/19. doi: 10.1016/j.bbabio.2009.09.005.
307 PubMed PMID: 19761752.

308 31. Howell N, Elson JL, Turnbull DM, Herrnstadt C. African Haplogroup L mtDNA sequences show violations
309 of clock-like evolution. Molecular biology and evolution. 2004;21(10):1843-54. Epub 2004/06/11. doi:
310 10.1093/molbev/msh184. PubMed PMID: 15190127.

311 32. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annual review of
312 pathology. 2010;5:297-348. Epub 2010/01/19. doi: 10.1146/annurev.pathol.4.110807.092314. PubMed PMID:
313 20078222; PubMed Central PMCID: PMCPMC3245719.

31. Chinnery PF, Gomez-Duran A. Oldies but Goldies mtDNA Population Variants and Neurodegenerative
315 Diseases. Frontiers in neuroscience. 2018;12:682. Epub 2018/10/30. doi: 10.3389/fnins.2018.00682. PubMed
316 PMID: 30369864; PubMed Central PMCID: PMCPMC6194173.

34. Salas A, Elson JL. Mitochondrial DNA as a risk factor for false positives in case-control association
studies. Journal of genetics and genomics = Yi chuan xue bao. 2015;42(4):169-72. Epub 2015/05/09. doi:
10.1016/j.jgg.2015.03.002. PubMed PMID: 25953355.

320 35. Torbergsen T, Oian P, Mathiesen E, Borud O. Pre-eclampsia--a mitochondrial disease? Acta obstetricia
321 et gynecologica Scandinavica. 1989;68(2):145-8. Epub 1989/01/01. doi: 10.3109/00016348909009902.
322 PubMed PMID: 2589041.

36. Widschwendter M, Schrocksnadel H, Mortl MG. Pre-eclampsia: a disorder of placental mitochondria?
Molecular medicine today. 1998;4(7):286-91. Epub 1998/09/23. doi: 10.1016/s1357-4310(98)01293-3. PubMed
PMID: 9743989.

37. Teran E, Hernandez I, Tana L, Teran S, Galaviz-Hernandez C, Sosa-Macias M, et al. Mitochondria and
 Coenzyme Q10 in the Pathogenesis of Preeclampsia. Frontiers in physiology. 2018;9:1561. Epub 2018/12/01.

doi: 10.3389/fphys.2018.01561. PubMed PMID: 30498451; PubMed Central PMCID: PMCPMC6249996.

329 38. Bybjerg-Grauholm J, Hagen CM, Gonçalves VF, Bækvad-Hansen M, Hansen CS, Hedley PL, et al.
 330 Complex spatio-temporal distribution and genogeographic affinity of mitochondrial DNA haplogroups in 24,216
 331 Danes. bioRxiv. 2017:148494.

332 39. Martinez-Redondo D, Marcuello A, Casajus JA, Ara I, Dahmani Y, Montoya J, et al. Human mitochondrial
333 haplogroup H: the highest VO2max consumer--is it a paradox? Mitochondrion. 2010;10(2):102-7. Epub
334 2009/11/11. doi: 10.1016/j.mito.2009.11.005. PubMed PMID: 19900587.

335 40. Gomez-Duran A, Pacheu-Grau D, Lopez-Gallardo E, Diez-Sanchez C, Montoya J, Lopez-Perez MJ, et al.
336 Unmasking the causes of multifactorial disorders: OXPHOS differences between mitochondrial haplogroups.
337 Hum Mol Genet. 2010;19(17):3343-53. Epub 2010/06/23. doi: 10.1093/hmg/ddq246. PubMed PMID:

338 20566709.

339 41. Stefano E, Marsigliante S, Vetrugno C, Muscella A. Is mitochondrial DNA profiling predictive for athletic
340 performance? Mitochondrion. 2019;47:125-38. Epub 2019/06/23. doi: 10.1016/j.mito.2019.06.004. PubMed
341 PMID: 31228565.

42. Hagen CM, Aidt FH, Hedley PL, Jensen MK, Havndrup O, Kanters JK, et al. Mitochondrial haplogroups
modify the risk of developing hypertrophic cardiomyopathy in a Danish population. PLoS One.

2013;8(8):e71904. Epub 2013/08/14. doi: 10.1371/journal.pone.0071904. PubMed PMID: 23940792; PubMed
 Central PMCID: PMCPMC3734310.

43. Amo T, Yadava N, Oh R, Nicholls DG, Brand MD. Experimental assessment of bioenergetic differences

caused by the common European mitochondrial DNA haplogroups H and T. Gene. 2008;411(1-2):69-76. Epub

348 2008/02/19. doi: 10.1016/j.gene.2008.01.007. PubMed PMID: 18280061; PubMed Central PMCID:

349 PMCPMC2270349.

44. Baudouin SV, Saunders D, Tiangyou W, Elson JL, Poynter J, Pyle A, et al. Mitochondrial DNA and survival
after sepsis: a prospective study. Lancet (London, England). 2005;366(9503):2118-21. Epub 2005/12/20. doi:
10.1016/S0140-6736(05)67890-7. PubMed PMID: 16360789.

Wojdemann KR, Shalmi AC, Christiansen M, Larsen SO, Sundberg K, Brocks V, et al. Improved firsttrimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of
9941 low-risk women. Ultrasound Obstet Gynecol. 2005;25(3):227-33. doi: 10.1002/uog.1834. PubMed PMID:
15736185.

357 46. De Villiers CP, Hedley PL, Placing S, Wøjdemann KR, Shalmi A-C, Carlsen AL, et al. Placental protein-13
358 (PP13) in combination with PAPP-A and free leptin index (fLl) in first trimester maternal serum screening for
359 severe and early preeclampsia. Clinical Chemistry and Laboratory Medicine (CCLM). 2018;56(1):65-74.

360 47. Hedley PL, Placing S, Wojdemann K, Carlsen AL, Shalmi AC, Sundberg K, et al. Free leptin index and
 361 PAPP-A: a first trimester maternal serum screening test for pre-eclampsia. Prenatal Diag. 2010;30(2):103-9. doi:
 362 10.1002/pd.2337. PubMed PMID: 20013873.

48. Christiansen M, Hedley PL, Placing S, Wøjdemann KR, Carlsen AL, Jørgensen JM, et al. Maternal serum
 resistin is reduced in first trimester preeclampsia pregnancies and is a marker of clinical severity. Hypertension
 in pregnancy. 2015;34(4):422-33.

49. Laigaard J, Sørensen T, Placing S, Holck P, Fröhlich C, Wøjdemann KR, et al. Reduction of the disintegrin
 and metalloprotease ADAM12 in preeclampsia. Obstetrics & Gynecology. 2005;106(1):144-9.

368 50. Benn M, Schwartz M, Nordestgaard BG, Tybjaerg-Hansen A. Mitochondrial haplogroups: ischemic
369 cardiovascular disease, other diseases, mortality, and longevity in the general population. Circulation.
370 2008;117(19):2492-501. Epub 2008/05/07. doi: 10.1161/CIRCULATIONAHA.107.756809. PubMed PMID:
371 18458168.

372 51. DSOG. Hypertension og præeklampsi 2018 [cited 2022 22-04-2022]. Available from: <u>www.dsog.dk</u>.

52. Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonak J, Lind K, et al. The real-time polymerase chain
reaction. Molecular aspects of medicine. 2006;27(2-3):95-125. Epub 2006/02/08. doi:

375 10.1016/j.mam.2005.12.007. PubMed PMID: 16460794.

53. Elson JL, Lightowlers RN. Mitochondrial DNA clonality in the dock: can surveillance swing the case?
Trends in genetics : TIG. 2006;22(11):603-7. Epub 2006/09/19. doi: 10.1016/j.tig.2006.09.004. PubMed PMID: 16979783.

54. Venter M, Tomas C, Pienaar IS, Strassheim V, Erasmus E, Ng WF, et al. MtDNA population variation in
Myalgic encephalomyelitis/Chronic fatigue syndrome in two populations: a study of mildly deleterious variants.
Sci Rep. 2019;9(1):2914. Epub 2019/03/01. doi: 10.1038/s41598-019-39060-1. PubMed PMID: 30814539;
PubMed Central PMCID: PMCPMC6393470.

55. Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? BJOG : an international journal of
obstetrics and gynaecology. 2004;111(4):298-302. Epub 2004/03/11. doi: 10.1111/j.1471-0528.2004.00071.x.
PubMed PMID: 15008762.

386 56. Redman CWG, Staff AC, Roberts JM. Syncytiotrophoblast stress in preeclampsia: the convergence point
387 for multiple pathways. American journal of obstetrics and gynecology. 2022;226(2S):S907-S27. Epub 20210202.
388 doi: 10.1016/j.ajog.2020.09.047. PubMed PMID: 33546842.

 Hagen CM, Gonçalves VF, Hedley PL, Bybjerg-Grauholm J, Bækvad-Hansen M, Hansen CS, et al.
 Schizophrenia-associated mt-DNA SNPs exhibit highly variable haplogroup affiliation and nuclear ancestry: Bigenomic dependence raises major concerns for link to disease. PloS one. 2018;13(12):e0208828.

392 58. Janssen BG, Munters E, Pieters N, Smeets K, Cox B, Cuypers A, et al. Placental mitochondrial DNA

content and particulate air pollution during in utero life. Environmental health perspectives. 2012;120(9):1346-

394 52. Epub 2012/05/26. doi: 10.1289/ehp.1104458. PubMed PMID: 22626541; PubMed Central PMCID:
 395 PMCPMC3440109.

S9. Bouhours-Nouet N, May-Panloup P, Coutant R, de Casson FB, Descamps P, Douay O, et al. Maternal
smoking is associated with mitochondrial DNA depletion and respiratory chain complex III deficiency in
placenta. American journal of physiology Endocrinology and metabolism. 2005;288(1):E171-7. Epub
2004/12/09. doi: 10.1152/ajpendo.00260.2003. PubMed PMID: 15585597.

400 60. Busnelli A, Lattuada D, Ferrari S, Reschini M, Colciaghi B, Somigliana E, et al. Mitochondrial DNA Copy

401 Number in Peripheral Blood in the First Trimester of Pregnancy and Different Preeclampsia Clinical Phenotypes
 402 Development: A Pilot Study. Reproductive sciences (Thousand Oaks, Calif). 2019;26(8):1054-61. Epub

403 2018/10/10. doi: 10.1177/1933719118804410. PubMed PMID: 30296910.

404 61. Qiu C, Hevner K, Enquobahrie DA, Williams MA. A case-control study of maternal blood mitochondrial
405 DNA copy number and preeclampsia risk. International journal of molecular epidemiology and genetics.
406 2012;3(3):237-44. Epub 2012/10/11. PubMed PMID: 23050054; PubMed Central PMCID: PMCPMC3459217.

- 409 Table 1. Clinical and demographic data of the preeclampsia (PE) cases and pregnancy controls.
- 410 'Control' is the group of healthy pregnancies. 'PE' is the preeclampsia patients. †Severity refers to the
- 411 severity of PE (PE 1=uncomplicated PE, PE 2=severe PE, PE 3=HELLP syndrome). Parity refers to the
- 412 number of times the woman has given birth.

	Ducanonar		Severity			
	control	All PE	PE 1	PE 2	PE 3 (HELLP)	
Number of Individuals	235	78	61	14	3	
Maternal Age* (years)	30.2 (4.3)	30.3 (4.9)	30.5 (5.2)	30.2 (3.4)	29.3 (3.7)	
Maternal Weight* (kg)	64.3 (19)	69.5 (11.6)	68.3 (11.8)	73.4 (10.9)	69 (8.3)	
Parity:						
0	55.7 %	61.0 %	60.7 %	64.3 %	66.7 %	
1	26.1 %	24.4 %	24.6 %	28.6 %	0.0 %	
≥ 2	18.3 %	14.1 %	14.8 %	7.1 %	33.3 %	
Gestational Age at birth (days)	283.1 (8)	273.9 (15.6)	277.5 (11.7)	263.6 (21.3)	249.7 (9.9)	
Birth Weight (g)	3591 (447.2)	3192 (729.4)	3293 (606.3)	2999 (945.7)	2045 (699.6)	

413

Haplogroup	PE (%)	Pregnancy	Population	
		Control (%)	Control (%)	
Α	0	2 (0.85)	n.d.	
В	0	1 (0.4)	n.d.	
С	0	1 (0.4)	n.d.	
Н	38 (48.7)	105 (44.7)	4244 (45.9)	
HV	0	5 (2.1)	412† (4.5)	
Ι	2 (2.6)	9 (3.9)	350* (3.8)	
J	5 (6.4)	16 (6.8)	843 (9.1)	
K	5 (6.4)	20 (8.5)	571 (6.2)	
L	1 (1.3)	1 (0.4)	n.d.	
Ν	1 (1.3)	4 (1.7)	n.d.	
R	0	1 (0.4)	n.d.	
Т	10 (12.8)	18 (7.6)	912 (9.9)	
U	11 (14.1)	35 (14.9)	35 (14.9)	
V	4 (1.7)	9 (3.8)	412† (4.5)	
W	0	1 (0.4)	n.d.	
X	0	1 (0.4)	n.d.	
Z	0	1 (0.4)	324 (3.5)	
W/I	2 (2.6)	10 (4.3)	350* (3.8)	
NA	1 (1.3)	5 (2.1)	n.d.	
Total	78 (100)	235 (100)	9254 (100)	

415 Table 2. Haplogroup distribution for preeclampsia (PE) pregnancies, control pregnancies and the

416 general population controls from Benn et al. 2008.

* Haplogroup was not distinguished. † haplogroup HV and V were not distinguished. NA not available. n.d. not
determined.

419 Table 3. Comparison of the haplogroup distribution in the healthy pregnancy control group and a

420 general Danish population. It shows that there were no significant differences (p-value > 0.05), it can

- 421 be concluded that the healthy pregnancy control group is representative for the general Danish
- 422 population.

Test setup	Pregnancy control/ population control, percentage	Fisher's exact test, p-value	Odds-ratio	95% CI
H vs. non-H	44.5/46.6	0.55	1.08	0.82-1.43
U vs. non-U	14.9/15.9	0.65	1.09	0.76-1.6
K vs. non-K	8.5/6.2	0.21	0.72	0.42-1.23
J vs. non-J	6.8/9.1	0.13	1.54	0.9-2.82
T vs. non-T	7.6/9.9	0.49	1.23	0.75-2.14
V vs. non-V	3.8/4.5	0.79	0.63	0.63-2.79

Test setup	PE/	Fisher's exact	Odds-ratio	95% CI
	pregnancy control,	test, p-value		
	percentage			
H vs. non-H	49/44	0.6	1.19	0.68-2
U vs. non-U	14/15	1	0.9	0.4-2
K vs. non-K	6/8	0.64	0.73	0.2-2.1
J vs. non-J	6/7	1	0.93	0.26-2.8
T vs. non-T	13/8	0.17	1.78	0.7-4.29
I vs. non-I	3/4	1	0.7	0.06-3.3
V vs. non-V	5/4	0.74	1.4	0.3-5
L vs. non-L	1/0.5	0.44	3	0.38-240
N vs. non-N	1/2	1	0.75	0.15-7.76

423 Table 4. Comparison of preeclamptic pregnancies and healthy control pregnancies for each haplogroup.

424 CI: confidence interval

425 Table 5. Comparison of preeclamptic pregnancies and a general population control from Benn et al

426 2008 for each haplogroup.

Test setup	PE/ Population control, percentage	Fisher's exact test, p-value	Odds-ratio	95% CI
H vs. non-H	49/46,6	0.73	1.09	0.67-1.74
U vs. non-U	14/15.9	0.64	0.83	0.4-1.6
K vs. non-K	6/6.2	1	1.01	0.3-2.5
J vs. non-J	6/9.1	0.44	1.44	0.66-2.85
T vs. non-T	13/9.9	0.32	1.78	0.7-4.29
V vs. non-V	5/4.5	0.79	1.09	0.3-3

427 CI: confidence interval



429

430 Figure 1. Haplogroup distribution and severity of PE. The x-axis shows the haplogroups, while the y-

431 axis is the number of PE patients. PE 1 is the mildest, uncomplicated form of preeclampsia (PE 1

432 n=61). PE 2 is severe preeclampsia (PE 2 n=14). PE 3 is preeclampsia complicated with HELLP

433 syndrome (PE 3 n=3). NA is the individuals with an unknown haplogroup.